FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents the use of NPP1 fusion protein in the manufacture of a medicine for the treatment of conditions associated with calcification, wherein the specified NPP1 protein contains an NPP1 component, a targeting fragment and an Fc site of an immunoglobulin, where the specified targeting fragment contains four or more consecutive negatively charged amino acid residues.
EFFECT: invention makes it possible to expand the range of medicines for the treatment of conditions associated with calcification.
12 cl, 29 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS OF CALCIFICATION AND THEIR APPLICATION METHODS | 2016 |
|
RU2757417C2 |
| POLYFUNCTIONAL PROTEIN MOLECULES CONTAINING DECORIN AND USE THEREOF | 2019 |
|
RU2823357C2 |
| NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS FOR TREATING DISEASES ASSOCIATED WITH MUSCULAR ATROPHY | 2016 |
|
RU2834707C1 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| MOLECULES TARGETING A TYPE III SECRETION SYSTEM | 2016 |
|
RU2759949C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| PROMOTERS FOR ENHANCING EXPRESSION IN POXVIRUSES | 2016 |
|
RU2753884C2 |
| UNIVERSAL ANTIBODY-MEDIATED BIOSENSOR | 2016 |
|
RU2746486C2 |
